Pegzilarginase
Medication
From Wikipedia, the free encyclopedia
Pegzilarginase, sold under the brand name Loargys, is a medication used for the treatment of hyperargininemia.[1][2]
| Clinical data | |
|---|---|
| Trade names | Loargys |
| Other names | AEB-1102, pegzilarginase-nbln |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1554H2492N416O463S6 |
| Molar mass | 34603.84 g·mol−1 |
The most common side effects include allergic reactions.[1]
Pegzilarginase was approved for medical use in the European Union in December 2023.[2]
Pegzilarginase was approved for medical use in the United States in February 2026.[3]
Medical uses
Society and culture
Legal status
In October 2023, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Loargys, intended for the treatment of hyperargininemia.[1] The applicant for this medicinal product is Immedica Pharma AB.[1] Pegzilarginase was approved for medical use in the European Union in December 2023.[2]
Brand names
Pegzilarginase is the international nonproprietary name.[4]
Pegzilarginase is sold under the brand name Loargys.[1]
